What clonal evolution patterns are seen in severe aplastic anemia treated with eltrombopag and immunosuppression?

Severe aplastic anemia often involves clonal hematopoiesis, where specific blood cell mutations exist before treatment. When patients receive a combination of immunosuppression and eltrombopag, these mutations become more common as the disease improves. Research shows that while the treatment helps blood counts recover, it also allows certain mutated cells to survive and expand, leading to distinct patterns of clonal evolution over the years.

What the research says

Studies tracking patients for up to 24 months found that the presence of somatic mutations increased significantly after starting therapy. At the start of treatment, about 30% of patients had these mutations, but this rose to nearly 80% by the 24-month mark. The average number of mutations per patient also grew from less than one at diagnosis to 2.5 after two years of treatment ¹.

Researchers identified two specific patterns of malignant clonal evolution in patients treated with this combination. The first pattern involves early evolution, which happens within the first year of therapy. These changes are primarily driven by aberrations on chromosome 7 and occur in about 5% of patients ²⁵.

The second pattern involves late evolution, which occurs 4 to 5 years after therapy begins. This later progression is initiated by the early selection of specific mutated clones that were often present before treatment started. Additionally, about 5% of patients developed paroxysmal nocturnal hemoglobinuria (PNH), a condition linked to the expansion of specific clones that existed prior to the start of treatment ²⁵.

What to ask your doctor

• What specific genetic mutations are present in my blood or bone marrow before I start treatment?
• How often will you test my blood for new clonal mutations while I am on eltrombopag and immunosuppression?
• What are the signs that my clonal evolution is following the early or late pattern described in recent studies?
• If I develop paroxysmal nocturnal hemoglobinuria (PNH) or other mutations, what are the next steps for managing my care?